Investors less impressed with Roche's ASCO data

Roche (ROG.VX) stole the show at the world's top cancer meeting, yet received a lukewarm response from investors over doubts that impressive clinical data will translate into big extra sales. Report

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.